"Teaming with BGI Tech, with its broad array of sequencing technologies, deep bioinformatics expertise, and extensive throughput capacity, will advance SA1kCGP to a whole new level," stated Dr. Anthony W. Tolcher, clinical director for START. "As a privately funded effort, SA1kCGP depends upon the shared vision and commitment of community-based donors, and the profound role BGI will play in the project further elevates the potential benefits that can be achieved for cancer patients through these generous contributions," he added.
SA1kCGP, launched in 2012, has already exceeded its initial goal of collecting samples from 1,000 patients. With a 90 percent consent rate and growing pace of enrollment, 1,200 patients have agreed to date to have their tumor tissues sampled and to allow for the transplantation of their tumors to mouse models in order to target genetic mutations for drug selection and development. SA1kCGP plans to sequence the cancer genomes of 10,000 patients at a fraction of the cost of other major cancer genome projects. The budget for SA1kCGP currently stands at $5 million, with approximately $1 million raised to date exclusively through community contributions.
SA1kCGP has assembled a world-class team of more than 200 San Antonio area cancer surgeons, pathologists, researchers and oncologists from numerous hospitals,
|Contact: Jia Liu|